{"abstract":"The National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Evaluation Patent License to MedGene Therapeutics, Inc. (\"MedGene\") located in Bethesda, MD to practice the inventions embodied in the patent applications listed Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/09/26/2016-23048.html","cfr_references":[],"citation":"81 FR 66048","comment_url":null,"comments_close_on":"2016-10-11","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before October 11, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-23048","effective_on":null,"end_page":66048,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/09/26/2016-23048.xml","html_url":"https://www.federalregister.gov/documents/2016/09/26/2016-23048/prospective-grant-of-start-up-exclusive-evaluation-patent-license-development-of-autologous","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-23048?publication_date=2016-09-26","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-09-26/2016-23048/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":188,"last_updated":"2026-07-26 04:15:02 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-09-26/pdf/2016-23048.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-23048.pdf?1474634754","publication_date":"2016-09-26","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/09/26/2016-23048.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T20:59:12Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":66048,"subtype":null,"title":"Prospective Grant of Start-Up Exclusive Evaluation Patent License: Development of Autologous Tumor-reactive T Cells Isolated From Peripheral Blood for the Treatment of Metastatic Follicular Thyroid Cancer and Metastatic Soft Tissue Sarcomas","toc_doc":"Development of Autologous Tumor-reactive T Cells Isolated from Peripheral Blood for the Treatment of Metastatic Follicular Thyroid Cancer and Metastatic Soft Tissue Sarcomas","toc_subject":"Proposed Start-up Exclusive Evaluation Patent License:","topics":[],"type":"Notice","volume":81}